8,11-二十碳二炔酸 | 82073-91-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 8,11-二十碳二炔酸
• 英文名称: 8,11-Eicosadiynoic acid
• 英文别名: icosa-8,11-diynoic acid
• CAS: 82073-91-4
• 化学式: C₂₀H₃₂O₂
• 分子量: 304.5
• InChiKey: AJBBHZDIKZCZAI-UHFFFAOYSA-N

物化性质

• 溶解度：
  0.15 M Tris-HCl pH 8.5：>1 mg/ml（来自油酸）； DMF：>100 mg/ml（来自油酸）； DMSO：>100 mg/ml（来自油酸）；乙醇：>100 mg/ml（来自油酸）； PBS pH 7.2：<100 μg/ml（来自油酸）

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  22
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1188440A1

  公开（公告）日：2002-03-20

  The present invention is to provide a stabilized pharmaceutical composition for oral use containing 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof having an antagonistic action to GPIIb/IIIa receptor and an oily base. The present invention is to further provide a method for the manufacture of a stabilized pharmaceutical composition for oral use by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base. The present invention is to furthermore provide a method for the stabilization of a pharmaceutical composition by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]-met hyl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base.

  本发明旨在提供一种口服用稳定药物组合物，该组合物含有对GPIIb/IIIa受体具有拮抗作用的1-乙基甲酯4-[[3-[对(羧基氨基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐以及油性碱。本发明进一步提供一种通过将 1-乙基甲酯 4-[[3-[p-(羧基脒基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐与油性碱复配来制造口服用稳定药物组合物的方法。本发明进一步提供了一种稳定药物组合物的方法，即用油性碱复配 1-乙基甲酯 4-[[3-[对(羧基氨基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐。
• Nanogel networks including polyion polymer fragments and biological agent compositions thereof
  申请人：——

  公开号：US20020136769A1

  公开（公告）日：2002-09-26

  The present invention relates to nanogel networks having at least one cross-linked polyionic polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.

  本发明涉及具有至少一种交联聚阴离子聚合物片段和至少一种非离子水溶性聚合物片段的纳米凝胶网络及其组合物，其中含有至少一种合适的生物制剂。
• Cross-linked ionic core micelles
  申请人：UNIVERSITY OF NEBRASKA BOARD OF REGENTS

  公开号：US20040228823A1

  公开（公告）日：2004-11-18

  The present invention provides polymer micelles with cross-linked ionic cores as delivery vehicles for therapeutics, diagnostics, nucleic acids, proteins, small molecules and the like. The present invention provides additionally methods of synthesis and uses for such micelles.

  本发明提供具有交联离子核的聚合物胶束，作为治疗、诊断、核酸、蛋白质、小分子等的输送载体。本发明还提供了此类胶束的合成方法和用途。
• COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF
  申请人：UNIVERSITY OF NEBRASKA BOARD OF REGENTS

  公开号：EP1005324B1

  公开（公告）日：2005-03-30
• PESTICIDAL AGGREGATES
  申请人：Innovaform Technologies, LLC

  公开号：EP2091323A2

  公开（公告）日：2009-08-26